Last year MSIF asked the MS community to get involved in a survey, setting the research priorities for the Cochrane MS and Rare Diseases of the Central Nervous System group (Cochrane). Cochrane collects, reviews and summarises all existing scientific evidence to try to answer specific questions. These summaries are called ‘systematic reviews’, and help ensure decisions about healthcare are evidence-based.

The survey was completed by 1190 people with and affected by MS and healthcare professionals from 55 different countries. 75% of the respondents were from people with MS (PwMS).

The priority list has been published in a scientific publication:

The Cochrane team will now be working on these priority questions:
  • Does MRI help predict disability worsening of PwMS?
  • What are the benefits and harms of treating PwMS with one disease-modifying drug compared to another?
  • Does psychological health affect disease progression in PwMS?
  • Does multidisciplinary care by teams of different social and health professionals improve health outcomes and experiences for PwMS?
  • What are the benefits and harms of exercise for PwMS?

Many thanks for all who took part and shared this survey to the MS community.

Page Tags: